Product Description
Overall, the global transcatheter tricuspid valve repair market was valued at $1.4 billion in 2025. This is expected to increase over the forecast period at a CAGR of 6.1% to reach $2.1 billion.
The full report suite on the global market for transcatheter tricuspid valve repair (TTVr) includes devices designed to reduce tricuspid regurgitation (TR).
The report includes data for 65 countries across 7 different regions which include North America, Latin America, Western Europe, Central & Eastern Europe, Middle East, Asia-Pacific, and Africa.
Data Types Included
- Unit Sales, Average Selling Prices, Market Size & Growth Trends
- Procedure Numbers
- Market Drivers & Limiters
- Market Forecasts Until 2032, and Historical Data to 2022
- Recent Mergers & Acquisitions
- Company Profiles and Product Portfolios
- Leading Competitors
Transcatheter Tricuspid Valve Repair Market Trends
Among the four heart valve repair markets, the tricuspid valve repair segment has recently gained significant attention from major manufacturers, driven by the large unmet clinical need and expanding indications for minimally invasive treatment. Abbott and Edwards Lifesciences are expected to continue investing heavily in product development, clinical research, and geographic expansion over the forecast period, further accelerating innovation and adoption within the transcatheter tricuspid valve repair (TTVr) market.
Transcatheter Tricuspid Valve Repair Market Share Insights
- Abbott was the leading competitor in the TTVr device market with a majority market share. The company’s TTVr system is the TriClip. The product was the first dedicated transcatheter tricuspid TEER system designed specifically for treating tricuspid regurgitation (TR). Abbott is expected to maintain its market leadership over the forecast period, supported by continued investment in tricuspid valve treatment technologies.
- Edwards Lifesciences was the second-largest competitor in the transcatheter tricuspid valve repair (TTVr) market in 2025. The company’s PASCAL System represents a minimally invasive transcatheter repair platform indicated for the treatment of tricuspid regurgitation in patients at high surgical risk. As part of Edwards’ broader transcatheter edge-to-edge repair (TEER) portfolio, the PASCAL Precision system received CE Mark approval in 2022 for both mitral and tricuspid repair, establishing Edwards Lifesciences as a key competitor to Abbott’s dedicated TriClip system within the expanding transcatheter tricuspid repair market.
- P&F Products & Features was the third-largest competitor in the transcatheter tricuspid valve repair (TTVr) market in 2025, participating in the segment through its TricValve® Transcatheter Bicaval Valve System. The TricValve system is a heterotopic transcatheter therapy consisting of self-expanding biological valves implanted in the superior and inferior vena cava to alleviate symptoms associated with severe tricuspid regurgitation, without direct intervention on the native tricuspid valve. The technology has obtained CE Mark approval and is commercially available in select international markets, with continued clinical evaluation supporting its use in high-risk patients who are not suitable candidates for surgical repair.
Transcatheter Tricuspid Valve Repair Market Segmentation Summary
- Transcatheter Tricuspid Valve Repair
Research Scope Summary
| Report Attribute | Details |
|---|---|
| Regions | North America (Canada, United States) Latin America (Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Dominican Republic, Ecuador, Guatemala, Mexico, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela) Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom) Central & Eastern Europe (Azerbaijan, Baltic States, Belarus, Bulgaria, Croatia, Czech Republic, Georgia, Greece, Hungary, Kazakhstan, Poland, Romania, Russia, Serbia, Slovakia, Slovenia, Turkey, Ukraine) Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates) Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Kyrgyzstan, Macao, Malaysia, Mongolia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Uzbekistan, Vietnam) Africa (Algeria, Egypt, Ethiopia, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda) |
| Base Year | 2025 |
| Forecast | 2026-2032 |
| Historical Data | 2022-2024 |
| Quantitative Coverage | Market Size, Market Shares, Procedure Numbers, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices. |
| Qualitative Coverage | Market Growth Trends, Market Limiters, Competitive Analysis & SWOT for Top Competitors, Mergers & Acquisitions, Company Profiles, Product Portfolios, FDA Recalls, Disruptive Technologies, Disease Overviews. |
| Data Sources | Primary Interviews with Industry Leaders, Government Physician Data, Regulatory Data, Hospital Private Data, Import & Export Data, iData Research Internal Database. |
CONTACT US FOR ADDITIONAL INFORMATION
For full segmentation and any questions regarding research coverage, please contact us for a complimentary demo of the full report.
